PMID- 15821785
OWN - NLM
STAT- MEDLINE
DCOM- 20050726
LR  - 20170427
IS  - 1699-3993 (Print)
IS  - 1699-3993 (Linking)
VI  - 41
IP  - 2
DP  - 2005 Feb
TI  - Hypothesis for the pathogenesis of type 1A diabetes.
PG  - 141-9
AB  - Type 1A (immune-mediated) diabetes results from T-cell-mediated specific 
      destruction of the islet beta cells that produce insulin (1). One can divide the 
      development of diabetes into a series of overlapping stages beginning with 
      genetic susceptibility and ending with complete beta cell destruction (2). The 
      dominant genetic susceptibility locus is the major histocompatibility complex 
      (MHC), also called the human leukocyte antigen (HLA) region in humans, and in 
      particular, immune response genes DR and DQ (3). Additionally, the existence of a 
      series of rare but informative "single-gene" disorders associated with autoimmune 
      diabetes indicates that a number of different immunologic lesions can lead to 
      autoimmune diabetes. The most common forms of type 1A diabetes are polygenic 
      (multifactorial) disorders with unidentified environmental factors contributing 
      to the disease. Given current information, it is now possible to predict the 
      development of type 1A diabetes (4, 5), and major efforts are under way to create 
      preventive therapies.
CI  - Copyright 2005 Prous Science. All rights reserved.
FAU - Jasinski, Jean M
AU  - Jasinski JM
AD  - Human Medical Genetics Program, University of Colorado Health Sciences Center, 
      Denver, Colorado, USA.
FAU - Eisenbarth, George S
AU  - Eisenbarth GS
LA  - eng
GR  - AI39213/AI/NIAID NIH HHS/United States
GR  - AI46374/AI/NIAID NIH HHS/United States
GR  - AI50864/AI/NIAID NIH HHS/United States
GR  - AI95380/AI/NIAID NIH HHS/United States
GR  - DK32082/DK/NIDDK NIH HHS/United States
GR  - DK32493/DK/NIDDK NIH HHS/United States
GR  - DK550970/DK/NIDDK NIH HHS/United States
GR  - DK55969/DK/NIDDK NIH HHS/United States
GR  - DK62718/DK/NIDDK NIH HHS/United States
GR  - M01 RR00051/RR/NCRR NIH HHS/United States
GR  - M01 RR00069/RR/NCRR NIH HHS/United States
GR  - P30 DK57516/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - Spain
TA  - Drugs Today (Barc)
JT  - Drugs of today (Barcelona, Spain : 1998)
JID - 101160518
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Type 1/*genetics/immunology/prevention & control
MH  - Humans
MH  - Immunotherapy
RF  - 58
EDAT- 2005/04/12 09:00
MHDA- 2005/07/27 09:00
CRDT- 2005/04/12 09:00
PHST- 2005/04/12 09:00 [pubmed]
PHST- 2005/07/27 09:00 [medline]
PHST- 2005/04/12 09:00 [entrez]
AID - 882664 [pii]
AID - 10.1358/dot.2005.41.2.882664 [doi]
PST - ppublish
SO  - Drugs Today (Barc). 2005 Feb;41(2):141-9. doi: 10.1358/dot.2005.41.2.882664.